Department of Pathology, New York University School of Medicine, New York, NY, 10016, USA.
Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, 240 E 38th Street, 22nd Floor, New York, NY, 10016, USA.
Acta Neuropathol Commun. 2022 May 8;10(1):71. doi: 10.1186/s40478-022-01371-2.
DNA methylation of cytosines in CpG sites throughout the genome is an epigenetic mark contributing to gene expression regulation. DNA methylation patterns are specific to tissue type, conserved throughout life and reflect changes during tumorigenesis. DNA methylation recently emerged as a diagnostic tool to classify tumors based on a combination of preserved developmental and mutation induced signatures. In addition to the tumor classification, DNA methylation data can also be used to evaluate copy number variation, assess promoter methylation status of specific genes, such as MGMT or MLH1, and deconvolute the tumor microenvironment, assessing the tumor immune infiltrate as a potential biomarker for immunotherapy. Here we review the role for DNA methylation in tumor diagnosis.
基因组中 CpG 位点胞嘧啶的 DNA 甲基化是一种表观遗传标记,有助于基因表达调控。DNA 甲基化模式具有组织特异性,在整个生命周期中保持保守,并反映肿瘤发生过程中的变化。DNA 甲基化最近成为一种基于保留的发育和突变诱导特征组合对肿瘤进行分类的诊断工具。除了肿瘤分类,DNA 甲基化数据还可用于评估拷贝数变异,评估特定基因(如 MGMT 或 MLH1)的启动子甲基化状态,并解析肿瘤微环境,评估肿瘤免疫浸润作为免疫治疗的潜在生物标志物。在这里,我们回顾了 DNA 甲基化在肿瘤诊断中的作用。